St. Jude Children's Research Hospital scientists have identified a link between a SARS-CoV-2 protein and the onset of multisystem inflammatory syndrome in children (MIS-C). MIS-C is a pediatric ...

In a small trial, Mass General Brigham researchers have found that a drug designed to treat celiac disease supported a more rapid return to normal activities for patients following COVID. New research ...

Study reveals a mechanism behind multisystem inflammatory syndrome in children (MIS-C). Early in the COVID-19 pandemic, some children fought off COVID with few, if any, symptoms, only to go into organ ...

Scientists have found a potential cause of multisystem inflammatory syndrome in children (MIS-C) linked to SARS-CoV-2 (COVID) infections. St. Jude Children's Research Hospital scientists have ...

Multisystem inflammatory syndromes in children represent a rare but serious post-infectious hyperinflammatory condition most notably observed in association with SARS-CoV-2. Clinically, affected ...

MIS-C is a serious inflammatory shock that affects children. It can occur several weeks after a COVID infection and can be life-threatening. Until now, however, the precise cause of the condition was ...

Faster resolution of GI symptoms, faster clearance of spike antigen, faster return to usual activities reported for children treated with larazotide. HealthDay News — Treatment of multisystem ...

Some children who had COVID developed a severe inflammatory response that could put them in the ICU. Scientists have learned why it happens. It’s one of the enduring mysteries of the pandemic: What ...

Larazotide, an oral drug, may effectively treat MIS-C by tightening the gut epithelial barrier, reducing systemic inflammation. The phase 2a trial showed faster resolution of GI symptoms and spike ...

Multisystem inflammatory syndrome in children (MIS-C), a serious disorder that develops after SARS-CoV-2 infection, could arise from latent infection of another pathogen, the Epstein-Barr virus (EBV).